Table 1

Main characteristics of the studies included in this meta-analysis

Study/year		Setting	Time	Population (years)	TKI start time	Intervention		Comparison		Outcomes
Study/year		Setting	Time	Population (years)	TKI start time	n1	Drug	n2	Drug	Outcomes
Randomised controlled trials
1	Biondi et al 201210	Europe	2004.1–2009.12	1–18	Post induction, good risk	46	Imatinib (300 mg/m²/day) + chemotherapy	44	Chemotherapy	OS, EFS, ADR
2	Shen et al 202022	China	2015.1–2018.9	7.8 (0–18)	After diagnosis, usually on D8 of remission induction	97	Imatinib (300 mg/m²/day) + chemotherapy	92	Dasatinib (80 mg/m².d) + chemotherapy	OS, EFS
Cohort studies
1	Zhang et al 201923	China	2008.1–2012.12	8.26 (2–12)	Post induction	54	Imatinib (0.6 g/day) + chemotherapy	40	Chemotherapy	OS, ADR
2	Wang and Jin 201624	China	2008.10–2016.1	9 (3–15)	Post induction	9	Imatinib (260–340 mg/m²/day) or DAS (40–80 mg/m²/day) + chemotherapy	9	Chemotherapy	OS, EFS
3	Guo et al 201525	China	2008.10–2013.12	8 (2–15)	D15 of remission induction	27	Imatinib (260–340 mg/m²/day) + chemotherapy	26	Chemotherapy	EFS, ADR
4	Liu and Zhu 201326	China	2003.10–2012.12	11 (2–17)	D15 of remission induction	38	Imatinib (260–340 mg/m²/day) + chemotherapy	54	Chemotherapy	OS, EFS

ADR, adverse drug reaction; EFS, event-free survival; OS, overall survival; TKI, tyrosine kinase inhibitors.